Prof. Albert Jeltsch, University of Stuttgart; Goran Kungulovski, University of Stuttgart; Rebekka Mauser, University of Stuttgart
The last two decades have seen an enormous increase of insight into the role of epigenetics in a vast array of diseases such as cancer, mental retardation and diabetes. In fact, the study of epigenetic mechanisms has become one of the most rapidly growing fields of biology, generating growing interest of the pharmaceutical industry.
Amongst others, epigenetic alterations involve post-transcriptional histone modifications (PTMs). Occurring in complex patterns, they form the so-called ‘histone code’. In order to decipher said code and unravel its involvement in disease, the characterization of co-occurring histone modifications is considered to be an important cornerstone. The invention at hand offers an innovative approach taking their analysis to another level.
Scientists at the University of Stuttgart developed an innovative method, in which two or more highly specific histone modification binding proteins are fused to form bi- or multispecific hybrid proteins. This construct allows the detection of co-occurring histone modifications (either on the same or different tails of one nucleosome) in one single step. The DNA gathered from the process can be analyzed using next-generation sequencing. Thus, it enables the investigation of co-occurring histone modification patterns on a genome-wide or locus-specific scale.
Contrary to conventional methods, the technique offers much improved sensitivity, is easy to perform and features consistent quality. Moreover, it requires only modest amounts of starting material.
- Detection of co-occurring PTMs in one single step
- Contrary to conventional techniques consistent quality
- Technically easy to perform
- Less time-consuming and less starting material needed than in conventional antibody mediated techniques
- No animal testing necessary in the production process
- Can be analyzed using next-generation sequencing
The Technologie-Lizenz-Büro GmbH is in charge of the commercialization of this technology and offers companies the possibility of obtaining licenses.
Successfully tested under laboratory conditions.
European and US patent applications are pending.